LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


Survey of Surgeons Indicates Strong Launch for EXPAREL


« Back to News


Project Scope We solicited 6000 general surgeons who are part of our proprietary Expert Network to participate in an Exparel usage survey. We queried the physicians on their current and expected use of Exparel, and other treatments for postoperative pain. We received responses from 100 surgeons, 93 of whom routinely make decisions regarding postoperative pain management. We present results from the survey in this note.

Exparel  Survey Results

On October 31, 2011, Pacira Pharmaceuticals (PCRX) received FDA approval for Exparel (bupivacaine liposome injectable suspension) 1.3% as an injectable treatment for postsurgical pain.  The drug is intended as a non-opioid alternative for the management of pain associated with surgery.  Exparel became available to hospitals and ambulatory care centers on April 9, 2012.  Prescription data indicated sales of $151k in April sales and an impressive $638k in sales for May.

Overall, the surgeons in our survey reported conducting approximately 3,260 surgical procedures requiring pain management per month. Respondents perform an average of 35 such procedures per month. Out of 100 surgeons surveyed, 93 reported making decisions regarding postoperative pain management.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design